{"entity":{"id":"nct06616636","kind":"trial","name":"A Phase Ib Study of Rezatapopt in Combination With Azacitidine in Patients With TP53Y220C Mutant Myeloid Malignancies (Acute Myeloid Leukemia or Myelodysplastic Syndrome)","aka":[],"tldr":"A phase 1 trial of Rezatapopt run by M.D. Anderson Cancer Center, now recruiting.","summary":"A Phase Ib Study of Rezatapopt in Combination With Azacitidine in Patients With TP53Y220C Mutant Myeloid Malignancies (Acute Myeloid Leukemia or Myelodysplastic Syndrome) is a phase 1 interventional study registered as NCT06616636 by M.D. Anderson Cancer Center, with 24 participants planned, started 2025-01-30, primary completion expected 2027-08-27. Conditions recorded: Myelodysplastic Syndrome, Acute Myeloid Leukemia. Interventions recorded: Azacitidine, Rezatapopt.","status":"recruiting","asOf":"2026-11-04","links":[{"label":"ClinicalTrials.gov NCT06616636","url":"https://clinicaltrials.gov/study/NCT06616636"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["aml","mds"],"sections":[],"technologies":[],"targets":[],"drugs":["rezatapopt"],"companies":["pmv-pharma"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06616636","phase":"1","setting":"A Phase Ib Study of Rezatapopt in Combination With Azacitidine in Patients With TP53Y220C Mutant Myeloid Malignancies (Acute Myeloid Leukemia or Myelodysplastic Syndrome)","sponsor":"M.D. Anderson Cancer Center","enrolled":24,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06616636/","neighbours":{"cancer":[{"id":"aml","kind":"cancer","name":"Acute myeloid leukaemia","route":"/cancers/aml/"},{"id":"mds","kind":"cancer","name":"Myelodysplastic syndromes / neoplasms (MDS)","route":"/cancers/mds/"}],"drug":[{"id":"rezatapopt","kind":"drug","name":"Rezatapopt","route":"/drugs/rezatapopt/"}],"company":[{"id":"pmv-pharma","kind":"company","name":"PMV Pharma","route":"/companies/pmv-pharma/"}]}}